platinum chemotherapy

Phase 3Small molecule

platinum chemotherapy is one of 71 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Ovarian CancerActive, not recruiting

NSCLCRecruiting

Advanced Non-Small Cell Lung Cancer (NSCLC)Not yet recruiting

Non-Small Cell Lung CancerPhase 3

Active, not recruiting

Ovarian CancerPhase 2

Active, not recruiting

NSCLCPreclinical

Recruiting

Advanced Non-Small Cell Lung Cancer (NSCLC)Phase 2

Not yet recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

platinum chemotherapy

Roche

Phase 3

2 2

Yervoy

Bristol-Myers Squibb

Preclinical

31 3

Gemzar

GGynecologic Oncology Group

Preclinical

72 4

PORTRAZZA

Eli Lilly

Preclinical

8 5

Imjudo

AstraZeneca

Preclinical

5 6

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 7

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 8

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 9

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Treatment

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

PreclinicalRecruiting

NSCLC

NCT05443126

Q2 2029

Phase 2Not yet recruiting

Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT07669779

Q3 2029

Phase 1Recruiting

Adult Subject

NCT06917079

Q4 2032

Phase 3Recruiting

Non-Small Cell Lung Cancer

NCT06899126

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Completed· Roche logo

Roche·Phase 3·NCT00883779·451 enrolled

A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination With Pembrolizumab Versus Platinum-based Chemotherapy in Combination With Pembrolizumab, as First-line Therapy in Participants With Locally Advanced Unresectable or Metastatic HER2 Overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer (DESTINY-Lung06)

Recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT06899126·686 enrolled

Tumors1 trial

Cohort of Well-differentiated Grade 3 Neuroendocrine Digestive Tumors

Completed·AAssistance Publique - Hôpitaux de Paris··NCT04365023·168 enrolled

Adult Subject1 trial

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Recruiting·TTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)·Phase 1·NCT06917079·387 enrolled

Ovarian Cancer1 trial

A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer

Completed·—·Phase 2·NCT03989336·84 enrolled

NSCLC1 trial

A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0031 in Patients With Advanced RET-altered Malignancies

Recruiting·EEllipses Pharma·Preclinical·NCT05443126·265 enrolled

1 more indication

Advanced Non-Small Cell Lung Cancer (NSCLC)1 trial

A Phase II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antitumor Efficacy of AK146D1 in Combination With AK112 or Other Anticancer Therapies in Patients With Advanced Non-Small Cell Lung Cancer

Not yet recruiting·AAkeso·Phase 2·NCT07669779·348 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for platinum chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — platinum chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for platinum chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

platinum chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q2 2029

Q3 2029

Q4 2032

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

Tumors1 trial

Adult Subject1 trial

Ovarian Cancer1 trial

NSCLC1 trial

Advanced Non-Small Cell Lung Cancer (NSCLC)1 trial

References

Drug Info

Quick Facts

Related News